Vitamin D and PTH Dynamics After Roux-en-Y Gastric Bypass: 5-Year Study
Overview
This five-year longitudinal study evaluated the relationship between serum vitamin D levels and parathyroid hormone (PTH) following Roux-en-Y gastric bypass (RYGB) surgery. Findings indicate that despite supplementation, secondary hyperparathyroidism (SHPT) remains prevalent, and higher vitamin D thresholds may be necessary to mitigate elevated PTH postoperatively.
Background
Roux-en-Y gastric bypass is an effective surgical intervention for morbid obesity but alters gastrointestinal anatomy, impacting nutrient absorption including calcium and vitamin D. These nutrients are critical regulators of parathyroid hormone, which often increases after obesity surgery and may affect bone health. Secondary hyperparathyroidism is common postoperatively despite supplementation, and optimal vitamin D levels for this population remain uncertain. This study investigates the longitudinal changes in PTH and vitamin D status over five years after RYGB.
Data Highlights
Timepoint
Serum 25(OH)D (nmol/l)
PTH (pmol/l)
SHPT Prevalence (%)
Preoperative
Data not routinely assessed
Data not routinely assessed
Baseline prevalence not specified
6 months
Measured routinely
Measured routinely
Data not specified
1 year
Measured routinely
Measured routinely
Data not specified
2 years
Measured routinely
Measured routinely
Data not specified
3-4 years
Measured routinely
Measured routinely
Data not specified
5 years
Grouped as <50, 50–74, 75–99, ≥100 nmol/l
Mean values and prevalence of SHPT assessed
SHPT defined as PTH >7.0 pmol/l with normal ionized calcium
Key Findings
Secondary hyperparathyroidism (SHPT) prevalence increased over time after RYGB despite calcium and vitamin D supplementation.
Patients with serum 25(OH)D levels ≥ 50 nmol/l had lower prevalence of SHPT compared to those with levels < 50 nmol/l, but SHPT remained common even at higher vitamin D levels.
Ionized calcium levels were maintained within normal ranges, indicating SHPT was not due to hypercalcemia.
Supplementation regimens included calcium carbonate and cholecalciferol, but compliance varied and adjustments were made to maintain target vitamin D levels.
Bone-specific alkaline phosphatase (B-ALP), a marker of bone turnover, was monitored and showed associations with PTH changes over time.
Optimal vitamin D thresholds post-RYGB may need to be higher than in non-surgical populations to effectively suppress PTH and reduce SHPT risk.
Clinical Implications
Clinicians should monitor PTH and vitamin D levels longitudinally after RYGB, as SHPT can develop or worsen despite standard supplementation. Maintaining serum 25(OH)D above 50 nmol/l is important, but higher targets may be necessary to prevent secondary hyperparathyroidism and protect bone health. Supplementation regimens should be individualized with attention to patient compliance and biochemical monitoring.
Conclusion
Five years after Roux-en-Y gastric bypass, secondary hyperparathyroidism remains prevalent despite supplementation, highlighting the need for higher vitamin D targets and vigilant long-term monitoring to optimize bone and mineral metabolism in this population.
References
Oslo University Hospital Study 2004-2009 -- Longitudinal analysis of vitamin D and PTH post-RYGB
